Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/FDA approves Medtronic's OmniaSecure defibrillation lead for left bundle branch placement, enhancing heart pacing therapy.
MDT
$80.48
+$0.01 +0.01%

FDA approves Medtronic's OmniaSecure defibrillation lead for left bundle branch placement, enhancing heart pacing therapy.

Market News
23 Mar 2026
PRNewsWire
View Source
Bullish
pluang ai news

Medtronic received FDA approval to use its OmniaSecure defibrillation lead in the left bundle branch (LBB) area, enabling conduction system pacing (CSP) that mimics natural heart function. This lead, the first FDA-approved for LBB placement and the smallest diameter on the market, supports advanced therapies like left bundle branch optimized cardiac resynchronization therapy (LOT-CRT). The approval is backed by clinical trial data showing high defibrillation success and low complication rates, expanding options for patients needing defibrillation and pacing. Medtronic plans to present longer-term results and continues to develop related CSP technologies.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App